Spots Global Cancer Trial Database for etrolizumab
Every month we try and update this database with for etrolizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors | NCT02136069 | Ulcerative Coli... | Etrolizumab Infliximab Placebo (IV) Placebo (Inject... | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02163759 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors | NCT02136069 | Ulcerative Coli... | Etrolizumab Infliximab Placebo (IV) Placebo (Inject... | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02171429 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02171429 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02165215 | Colitis, Ulcera... | Etrolizumab Placebo | 18 Years - 80 Years | Hoffmann-La Roche | |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors | NCT02163759 | Ulcerative Coli... | Adalimumab Adalimumab Plac... Etrolizumab Etrolizumab Pla... | 18 Years - 80 Years | Hoffmann-La Roche |